Sustainable Insight Capital Management LLC Has $4.03 Million Stake in Abbott Laboratories $ABT

Sustainable Insight Capital Management LLC lowered its stake in Abbott Laboratories (NYSE:ABT) by 47.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,633 shares of the healthcare product maker’s stock after selling 26,252 shares during the quarter. Abbott Laboratories makes up approximately 1.8% of Sustainable Insight Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Sustainable Insight Capital Management LLC’s holdings in Abbott Laboratories were worth $4,030,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ABT. IMG Wealth Management Inc. boosted its holdings in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the period. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the first quarter worth about $27,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter valued at approximately $30,000. Vision Financial Markets LLC acquired a new stake in Abbott Laboratories in the first quarter valued at about $33,000. Finally, Accent Capital Management LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT opened at $124.91 on Friday. The firm has a 50-day moving average price of $130.91 and a 200-day moving average price of $131.43. The company has a market capitalization of $217.20 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The business had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. During the same quarter in the prior year, the firm posted $1.21 EPS. Abbott Laboratories’s revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Daiwa Capital Markets lifted their target price on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Sanford C. Bernstein raised their target price on Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Morgan Stanley upped their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Evercore ISI cut their target price on Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.